Abstract:Sulfasalazine needs frequent daily dosing and the administration of numerous tablets per day pose challenges to patient compliance, contributing to increased adverse effects and difficulties in disease control. These inconveniences result in less effective treatment for arthritis associated with inflammatory bowel disease i.e. ulcerative colitis etc. To improve drug bioavailability, a delayed-release mechanism that releases the drug at the colon is necessary. To develop and optimise colon-targeted controlled release bilayer tablets coated with pH-dependent polymers. The bilayer tablets containing the immediate release part and sustained release part were developed. The tablets were coated with enteric-coated with Eudragit® S-100 and L-100 to achieve release in the colon. Granule properties and tablets were evaluated. The physicochemical parameters of the tablets were evaluated including, stability study, and drug release in 0.1 N HCl (pH 1.2), pH 6.8 phosphate buffer, pH 7.4 phosphate buffer for 2, 1, and up to 24 hours respectively. Radiographic imaging and in vivo pharmacokinetic studies were also done in Rabbits. The bilayer tablets containing immediate and sustained release were successfully developed for the colon targeting. The granule properties were found within the acceptable range indicating good flow properties. The physicochemical properties of the tablets were also found acceptable. The tablets did not show release in 0.1 N HCl and 6.8 phosphate buffer but drug release was found under control in the 7.4 pH buffer. Sulfasalazine coated bilayer tablets were found stable and no significant changes were observed in the stability studies. Based on the X-ray studies, the formulated tablet remained discernible in the stomach, small intestine, and colon for a duration of up to 24 hours. Finally, by the 32nd hour, the tablet was no longer visible in the X-ray examination, leading to the conclusion of complete drug release. The drug concentration in plasma remained within the therapeutic range for up to 24 hours in vivo . These novel formulations present substantial advantages, providing prolonged targeted drug release and reducing systemic adverse effects. The results suggest promising potential for treating arthritis in Inflammatory bowel disease (IBD) patients, offering a solution to current delivery systems.

Core-shell tablets designed for modified and sequential release of ibuprofen and rabeprazole

Preparation, Characterization and Pharmacokinetics Evaluation of the Compound Capsules of Ibuprofen Enteric-Coated Sustained-Release Pellets and Codeine Phosphate Immediate-Release Pellets

Design and Evaluation of in Vivo Bioavailability in Beagle Dogs of Bilayer Tablet Consisting of Immediate Release Nanosuspension and Sustained Release Layers of Rebamipide.

Preparation, Characterization And In Vitro Release Properties Of Ibuprofen-Loaded Microspheres Based On Polylactide, Poly(Epsilon-Caprolactone) And Their Copolymers

Preparation, characterization and in vitro release properties of ibuprofen-loaded microspheres based on polylactide, poly(ε-caprolactone) and their copolymers

Formulation and development of novel Sulfasalazine bilayer tablets for the treatment of arthritis associated with IBD: In-vitro and In-vivo Investigations

Design, Development and In vivo Evaluation of Core in Cup Tablets of Budesonide

In Vitro and Biological Evaluation of Oral Fast-Disintegrating Films Containing Ranitidine HCl and Syloid® 244FP-Based Ternary Solid Dispersion of Flurbiprofen

Gastroretentive Matrix Tablets of Boswellia Oleogum Resin: Preparation, Optimization, In Vitro Evaluation, and Cytoprotective Effect on Indomethacin-Induced Gastric Ulcer in Rabbits

Nano-engineered solutions for ibuprofen therapy: Unveiling advanced co-delivery strategies and nanoparticle systems

Mucoadhesive elementary osmotic pump tablets of trimetazidine for controlled drug delivery and reduced variability in oral bioavailability

Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability

Cubic Phase Nanoparticles for Sustained Release of Ibuprofen Formulation Characterization and Enhanced Bioavailability Study

Evaluation of A Non-Aqueous Ibuprofen-Phospholipid Complex Formulation in Rats

Formulation, Characterization and In Vitro Evaluation of Mesalamine and Bifidobacterium bifidum Loaded Hydrogel Beads in Capsule System for Colon Targeted Delivery

Core–Shell Chitosan Microcapsules for Programmed Sequential Drug Release

Ibuprofen Release Kinetics from Controlled-Release Tablets Granulated with Aqueous Polymeric Dispersion of Ethylcellulose II: Influence of Several Parameters and Coexcipients.

Preparation and Evaluation of a Novel Delayed-Onset Sustained-Release System of Propranolol Hydrochloride

Studies on Drug Release Kinetics from Ibuprofen-Carbomer Hydrophilic Matrix Tablets: Influence of Co-Excipients on Release Rate of the Drug

Optimization of ranitidine hydrochloride based on stability performance in directly compressible immediate and sustained release formulations

Liquid-like Oral Sustained-Release System Based on Acid-Sensitive in situ Hydrogel for Alleviate Gastrointestinal Side Effects of Indobufen